IMDRF Tackles Confusion Over Clinical Evidence Expectations for Device Software
This article was originally published in Clinica
If all goes to plan, the International Medical Device Regulators Forum will have completed by July a draft guidance that explores when and to what level clinical evaluation and evidence is necessary or acceptable to support marketing authorizations of software as a medical device (SaMD).
You may also be interested in...
Uncertainties over clinical and cost effectiveness are behind the health technology assessment body’s recommendation against Spravato's use on the National Health Service.
New medicines under evaluation at the European Medicines Agency.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).